| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism/Metabolites...Due to its low chronic toxicity, hydroquinone monobenzyl ether is predicted to be readily metabolized in the same manner as phenol.
|
|---|---|
| References | |
| Additional Infomation |
Monobenzone is a monobenzyl ether of hydroquinone. It is a topical medication used to treat skin depigmentation. It inhibits melanin synthesis, acts as a dermatological drug, and is an sensitizer. Its function is similar to that of hydroquinone. Monobenzone is a white, almost odorless crystalline powder, readily soluble in alcohol and practically insoluble in water. It depigments mammalian skin by increasing melanin secretion from melanocytes. It may also cause melanocyte destruction and permanent depigmentation. Monobenzone is a depigmenting agent. The mechanism of action of Monobenzone is the inhibition of melanin synthesis. The physiological effect of Monobenzone is achieved through its depigmenting activity. Monobenzone is a monobenzyl ether of hydroquinone with local depigmenting activity. Although its exact depigmenting mechanism is not fully understood, the metabolites of Monobenzone appear to have cytotoxic effects on melanocytes. Furthermore, the depigmentation effect may be mediated by the inhibition of tyrosinase, an enzyme essential for melanin synthesis, leading to permanent skin depigmentation.
Drug Indications Topical use for the treatment of skin depigmentation (vitiligo). FDA Label Mechanism of Action Monobenzone is a depigmenting agent whose mechanism of action is not fully understood. It is presumed to increase melanin secretion from melanocytes. This effect is unstable and may take one to four months to appear, during which time existing melanin is lost with normal shedding of the stratum corneum. Hyperpigmented skin appears to fade faster than normal skin, and sun exposure reduces the depigmentation effect of the drug. Histological studies of skin depigmentation following topical application of Monobenzone have shown results similar to vitiligo, with intact epidermis but a lack of identifiable melanocytes. ...Interference with melanin biosynthesis. It inhibits tyrosinase, thereby preventing the conversion of tyrosine to dihydroxyphenylalanine (a precursor to melanin). |
| Molecular Formula |
C13H12O2
|
|---|---|
| Molecular Weight |
200.237
|
| Exact Mass |
200.083
|
| CAS # |
103-16-2
|
| PubChem CID |
7638
|
| Appearance |
LUSTROUS LEAFLETS FROM WATER
WHITE CRYSTALLINE POWDER |
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
359.1±17.0 °C at 760 mmHg
|
| Melting Point |
119-120 °C(lit.)
|
| Flash Point |
213.4±5.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.603
|
| LogP |
2.96
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
167
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C1C([H])=C([H])C(=C([H])C=1[H])O[H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
VYQNWZOUAUKGHI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2
|
| Chemical Name |
4-phenylmethoxyphenol
|
| Synonyms |
AI3-14325; Benoquin; Monobenzone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~499.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9940 mL | 24.9700 mL | 49.9401 mL | |
| 5 mM | 0.9988 mL | 4.9940 mL | 9.9880 mL | |
| 10 mM | 0.4994 mL | 2.4970 mL | 4.9940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
